Complement inhibitors for age-related macular degeneration

Michael Williams, Gareth J McKay, Usha Chakravarthy

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)
485 Downloads (Pure)


Given the relatively high prevalence of age-related macular degeneration (AMD) and the increased incidence of AMD as populations age, the results of trials of novel treatments are awaited with much anticipation. The complement cascade describes a series of proteolytic reactions occurring throughout the body that generate proteins with a variety of roles including the initiation and promotion of immune reactions against foreign materials or micro-organisms. The complement cascade is normally tightly regulated, but much evidence implicates complement overactivity in AMD and so it is a logical therapeutic target in the treatment of AMD.
Original languageEnglish
Article numberCD009300
Number of pages20
JournalCochrane Database of Systematic Reviews
Issue number1
Publication statusPublished - 15 Jan 2014


Dive into the research topics of 'Complement inhibitors for age-related macular degeneration'. Together they form a unique fingerprint.

Cite this